Proteros biostructures has collaborated with Priaxon to develop lead compounds for high value protein-protein interaction (PPI) drug targets.
The combination of Proteros' structure guided discovery with Priaxon's PPI-directed drug discovery platforms will be focused on the identification of novel small molecule modulators for PPI targets, according to the companies.
As part of the Lead Discovery Collaboration, Proteros will apply its integrated lead discovery expertise and technologies in the field of structural biology, biophysics and screening.
Priaxon will apply its drug discovery platform Priaxplore, which combines PPI focused chemical space with chemoinformatic methods for the identification of potential PPI modulators.
Priaxon CEO Dr. Juergen Kolb said that the combination of Proteros' strength in structural biology and biophysics with the PPI focused drug discovery platform Priaxplore forms an excellent basis to make PPI targets of high interest by small molecule modulators.
Proteros CEO Dr. Torsten Neuefeind said, "PPIs are a big challenge in drug discovery and the use of structural information, computational chemistry and Priaxons' validated chemistry approach allows us to respond to the industry demand for such targets in a unique manner."